Clinical Trials
41 trialsA Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
STEALTH-001
KaliVir Immunotherapeutics
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Pfizer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Molecure S.A.
Study of Continuous OSI-906 Dosing
Astellas Pharma Inc
Study of Intermittent OSI-906 Dosing
Astellas Pharma Inc
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
Canadian Cancer Trials Group
A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
MICROBIOME
Imperial College London
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
Weill Medical College of Cornell University
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
Celldex Therapeutics
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
Spectroscopy With Surface Coils and Decoupling
Memorial Sloan Kettering Cancer Center
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Memorial Sloan Kettering Cancer Center
Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma
Valerio Therapeutics
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Rapamycin With Grapefruit Juice for Advanced Malignancies
University of Chicago
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
Altor BioScience
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
National Cancer Institute (NCI)
A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Eisai Inc.
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
National Institutes of Health Clinical Center (CC)
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
National Institutes of Health Clinical Center (CC)
ABT-751 in Treating Young Patients With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
Takeda
Phase 1 Study of OSI-930 in Cancer Patients
Astellas Pharma Inc
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics LLC.
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Institutes of Health Clinical Center (CC)